Memantine Enanthate Transdermal Patch for Stable Skin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing percutaneous absorption preparations containing memantine suffer from low skin permeability, skin irritation, and stability issues due to drug crystal precipitation, making them unsuitable for long-term use in treating dementia.
Innovation Solution
A percutaneous absorption preparation using memantine enanthate, which exhibits high solubility, excellent skin permeability, minimal crystal precipitation, and reduced skin irritation, is developed, comprising a drug-containing layer with memantine enanthate, a solubilizer, and a pressure-sensitive adhesive.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If memantine free base is used to improve skin permeability, then skin permeability increases, but skin irritation becomes severe
Solution Approach 1:
The patent changes the chemical form of memantine from free base to enanthate salt, which fundamentally alters the physicochemical parameters. This transformation reduces skin irritation while maintaining adequate skin permeability, resolving the contradiction between penetration and safety
Solution Approach 2:
The enanthate salt acts as an intermediary form between memantine free base and its hydrochloride salt. It provides a balanced profile that mediates between the high permeability of free base and the low irritation of hydrochloride, achieving both goals simultaneously
2Ease of manufacture
If memantine hydrochloride is used for oral administration, then it is readily available, but it crystallizes over time causing reduced skin permeability and adhesive strength
Solution Approach 1:
The patent changes the salt form from hydrochloride to enanthate, which has different crystallization characteristics. This parameter change prevents crystal precipitation and maintains both skin permeability and adhesive strength over time, resolving the stability issue
Solution Approach 2:
By selecting enanthate salt formulation, the patent prevents crystal precipitation before it can occur. This proactive approach cushions against the potential problem of crystallization that would otherwise reduce formulation stability and performance
3Reliability
If memantine free base is used to achieve high skin permeability, then penetration increases, but volatility decreases effective drug amount and stability
Solution Approach 1:
The patent changes the physical state and chemical form of memantine from volatile free base to non-volatile enanthate salt. This parameter change eliminates volatility-related drug loss while maintaining adequate skin permeability through the salt's different physicochemical properties
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The preparation achieves continuous drug release over a long period with minimal skin irritation, providing an effective alternative to oral administration for dementia treatment.
Implementation Method 1
memantine enanthate, which exhibits high solubility, excellent skin permeability
Data Source
Figure 1~2
Figure 3~4
Figure 5~7
AI summary
The present invention provides a percutaneous absorption preparation for the treatment of dementia, comprising a support layer, a drug-containing layer, and a release layer, wherein the drug-containing layer comprises memantine enanthate, a solubilizer, and a pressure-sensitive adhesive. The percutaneous absorption preparation for the treatment of dementia according to the present invention does not form crystal precipitation, shows high skin permeability, allows easy clinical control of the usable patch area, and allows control of the absorption rate by adjusting the rate of release, thus minimizing skin irritation, and provides an economic benefit of minimal waste of the drug while also preventing overdose of the drug.